Sotiria Boukouvala

Dr. Sotiria Boukouvala


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2015 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
LKLv Kalman
Lv Kalman
JAJag Agúndez
Jag Agúndez
MAM Lindqvist Appell
M Lindqvist Appell
JBJl Black
Jl Black
GBGc Bell
Gc Bell
UZUm Zanger
Um Zanger

6 August 2015 in Scientific Reports
Verified
Journal Article
Open access
EKEleni P. Karagianni
Eleni P. Karagianni
EKEvanthia Kontomina
Evanthia Kontomina
BDBritton Davis
Britton Davis
BKBarbara Kotseli
Barbara Kotseli
TTTheodora Tsirka
Theodora Tsirka
SBSotiria Boukouvala
Sotiria Boukouvala
Plant-pathogenic fungi and their hosts engage in chemical warfare, attacking each other with toxic products of secondary metabolism and defending themselves via an arsenal of xenobiotic metabolizing enzymes. One such enzyme is homologous to arylamine N-acetyltransferase (NAT) and has been identified in Fusarium infecting cereal plants as responsible for detoxification of host defence compound 2-benzoxazolinone. Here we investigate functional diversification of NAT enzymes in crop-compromising species of Fusarium and Aspergillus, identifying three groups of homologues: Isoenzymes of the first group are found in all species and catalyse reactions with acetyl-CoA or propionyl-CoA. The second group is restricted to the plant pathogens and is active with malonyl-CoA in Fusarium species infecting cereals. The third group generates minimal activity with acyl-CoA compounds that bind non-selectively to the proteins. We propose that fungal NAT isoenzymes may have evolved to perform diverse functions, potentially relevant to pathogen fitness, acetyl-CoA/propionyl-CoA intracellular balance and secondary metabolism.

1 January 2013 in BMC Ecology and Evolution
Verified
Journal Article
Open access
PDF file
ASAudrey Sabbagh
Audrey Sabbagh
JMJulie Marin
Julie Marin
CVCharlotte Veyssière
Charlotte Veyssière
ELEmilie Lecompte
Emilie Lecompte
SBSotiria Boukouvala
Sotiria Boukouvala
BCBrigitte Crouau-Roy
Brigitte Crouau-Roy
The arylamine N-acetyltransferases (NATs) are a unique family of enzymes widely distributed in nature that play a crucial role in the detoxification of aromatic amine xenobiotics. Considering the temporal changes in the levels and toxicity of environmentally available chemicals, the metabolic function of NATs is likely to be under adaptive evolution to broaden or change substrate specificity over time, making NATs a promising subject for evolutionary analyses. In this study, we trace the molecular evolutionary history of the NAT gene family during the last ~450 million years of vertebrate evolution and define the likely role of gene duplication, gene conversion and positive selection in the evolutionary dynamics of this family.

10 September 2021 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
VGVasiliki Garefalaki
Vasiliki Garefalaki
MPMaria-Giusy Papavergi
Maria-Giusy Papavergi
OSOlga Savvidou
Olga Savvidou
GPGeorgia Papanikolaou
Georgia Papanikolaou
TFTamás Felföldi
Tamás Felföldi
SBSotiria Boukouvala
Sotiria Boukouvala
Arylamines are encountered as industrial chemicals or by-products of agrochemicals that may constitute highly toxic contaminants of soils and groundwaters. Although such chemicals may be recalcitrant to biotransformation, they can be enzymatically converted into less toxic forms by some bacteria.

31 October 2019 in World Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
VGVasiliki Garefalaki
Vasiliki Garefalaki
EKEvanthia Kontomina
Evanthia Kontomina
CICharalambos Ioannidis
Charalambos Ioannidis
OSOlga Savvidou
Olga Savvidou
CVChristina Vagena-Pantoula
Christina Vagena-Pantoula
SBSotiria Boukouvala
Sotiria Boukouvala

23 December 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GPGeorgia Papanikolaou
Georgia Papanikolaou
EPEstella S. Poloni
Estella S. Poloni
Jose AgundezJose Agundez
Jose Agundez
RTRaquel L.F. Teixeira
Raquel L.F. Teixeira
EBErin C. Boone
Erin C. Boone
AGAndrea Gaedigk
Andrea Gaedigk
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 ( NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines. Systematic nomenclature describing NAT2 variation is essential for pharmacogenetic testing, genotype interpretation, and translation to phenotype in research and clinical settings. This GeneFocus provides an overview of NAT2 variation and describes important changes to its star allele‐based nomenclature that were made as it was transitioned to PharmVar in March 2024. We also highlight and discuss challenges regarding the characterization of allelic variation and determination of allele frequencies across world populations. The “new” NAT2 PharmVar nomenclature is utilized by ClinPGx (formerly PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).